Carregant...
Pseudoprogression as an adverse event of glioblastoma therapy
We explored predictive factors of pseudoprogression (PsP) and its impact on prognosis in a retrospective series of uniformly treated glioblastoma patients. Patients were classified as having PsP, early progression (eP) or neither (nP). We examined potential associations with clinical, molecular, and...
Guardat en:
| Publicat a: | Cancer Med |
|---|---|
| Autors principals: | , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley and Sons Inc.
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5727237/ https://ncbi.nlm.nih.gov/pubmed/29105360 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1242 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|